HIV Infections Clinical Trial
Official title:
Screening, Brief Intervention, and Referral to Treatment for Offenders
The purpose of the study is to determine whether SBIRT is an effective intervention with inmates and to estimate the costs of providing SBIRT to this population.
Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based
practice that has been found to be effective in reducing alcohol and illicit drug use,
mainly among persons recruited in medical centers, primary care offices, emergency rooms,
and colleges and universities. But SBIRT has the potential to be applicable to other
populations that have, or that are at risk for, substance use problems. In particular,
offenders have high prevalence of drug and alcohol use at varying levels of severity and
often do not receive adequate intervention, either because of limited availability of
programs, low motivation, or lack of awareness of the consequences of their substance use.
The scientific aims of the study are:
1. Assess the effectiveness of SBIRT with offenders in terms of participation in brief
intervention (if so indicated) and enrollment in treatment (if so indicated).
2. Assess the effectiveness of SBIRT with offenders in terms of drug use, criminal
activity, and criminal justice involvement at 12 months following baseline.
3. Determine whether there are differences in acceptability, participation, and outcomes
between men and women.
4. Determine the cost of providing the SBIRT intervention with this population.
The clinical aims of the study are:
1. To complement the use of SBIRT within Los Angeles County's substance abuse treatment
system.
2. To expand prevention and treatment options for offenders with substance abuse problems.
To our knowledge, this would be the first rigorous test of SBIRT with an offender
population.
We will recruit inmates at two Los Angeles County Sheriff jail facilities, one for men and
one for women (25% of total sample), and randomly assign them to the treatment (SBIRT) group
(N =400) or to the control (no intervention) group (N = 400). Baseline demographic data will
be collected. Subjects in both groups will be screened for substance use risk using The
Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World
Health Organization. Control subjects will receive only their risk score and informational
materials regarding the health risks of substance use. Experimental subjects, in addition to
their risk score and informational materials, will also receive a brief intervention and a
referral to treatment appropriate to their risk score from trained health educators. The
health educators will be provided by Homeless Health Care, Los Angeles. Twelve months after
study admission, all study participants will be contacted for a follow-up interview. We will
obtain records-based data on arrests and jail incarceration over the follow-up period from
the Sheriff's Department and the California Department of Justice. We will also collect
subject participation in publicly-funded treatment from the Substance Abuse Prevention and
Control Division of the Los Angeles County Department of Health.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |